Abstract:Abstract A 52-year-old woman presented in 1999 with an atypical erythematous plaque on her left thigh containing a flesh-coloured nodule surrounded by four pink scaly papules. She had no significant past medical, drug or family history. Excision of the nodule revealed an amelanotic malignant melanoma (MM) of Breslow thickness (BT) 1 mm. Biopsies of the four surrounding lesions confirmed satellite MM in one, with no radiological evidence of metastases. She received adjuvant interferon therapy for 1 year. Repeat imaging was normal. Eighteen years later, she developed a new pigmented lesion on her left thigh confirmed as MM (0.9 mm BT), with three further erythematous plaques on the left thigh reported as (i) proximal left-thigh MM (1.08 mm BT), (ii) middle-left-thigh amelanotic MM (0.6 mm BT) and (iii) left-thigh MM (1.7 mm BT). Wide local excision (WLE) failed to obtain histological clearance of (i) and (iii), with mildly dysplastic naevus and melanoma in situ (MiS), respectively, at the peripheral margins. Reflective confocal microscopy (RCM) was used to guide further surgery, with continued incompletely excised MiS and field change at the margins. Eighteen months later she presented with another MiS and MM (0.5 mm BT) on the left thigh. Imiquimod 5% once daily for 8 weeks to the affected area was instigated to treat any residual in situ component. BRAF, CDKN2A, CDK4 and BAP1 showed no pathological variants, and xeroderma pigmentosum testing was negative. Six months later a further MM (1.2 mm BT) on the left thigh was treated with WLE and skin graft. Sentinel lymph node biopsy was deemed not possible due to previous multiple surgical excisions. Ultrasound groin scan and whole-body FDG-PET computed tomography showed no occult metastases. Several months later, another MM (0.5 mm BT) was excised at the edge of the graft site. Residual dysplastic lentiginous proliferation at the edge with no MM was reported on the 1-cm WLE. This represents a complex case with recurrent MM, often indistinguishable from primary MM histologically. Widespread dysplastic field change evidenced by involvement at the edges of the WLEs and the RCM images was also challenging. RCM can be a noninvasive adjunct in identification of superficial skin tumours. Adjuvant interferon therapy for high-risk MM has demonstrated an increase in disease-free survival (Petrella T, Verma S, Spithoff K et al. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systemic review and practice guideline. Clin Oncol 2012; 24: 413–23). This may have contributed to the 18-year delay between her first and second melanomas, as well as her complex, recurrent presentations and ongoing local confinement of the MM to the left thigh with lack of disease progression.

Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation

Long-term survival of kidney-transplant recipient with donor-transmitted malignant melanoma after provoked rejection

Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation

Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

International incidence of melanoma in heart transplant recipients: a meta-analysis

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

Successful treatment of gastric cancer 10 years after heart transplantation: A case report

A Rare Case of Metastatic Adrenal Melanoma

Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors

Recurrent rejections after liver transplantation for hepatocellular carcinoma with stem cell features in an adult patient

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

Fighting malignancy in organ transplant recipients

Skin cancer in renal transplant recipients: outcomes from a safety net hospital in Boston

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells

CPC10 A curious case of recurrent melanomas and field change confined to the left thigh over 25 years

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study

Current Advances in the Treatment of BRAF-Mutant Melanoma

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Cardiotoxicity of Systemic Melanoma Treatments